TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00897949
Drug: rizatriptan benzoate (MK0462)
Normalized name: Rizatriptan Benzoate
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
Study: NCT04026685
Drug: Phenylephrine infusion
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
Study: NCT02508402
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using
Study: NCT04026685
Drug: Phenylephrine infusion and Ringer-Acetate bolus
Normalized name: calcium acetate and magnesium carbonate
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
Study: NCT00114621
Drug: Anthrax Vaccine
Normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01712919
Drug: Concurrent chemotherapy with paclitaxel and nedaplatin
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
Study: NCT02122718
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01553747
Drug: Eluxadoline
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablets twice daily
Study: NCT00097045
Drug: omega interferon
Normalized name: Omega interferon
DrugBank: Human interferon omega-1 (DB05472)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00097045
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02795637
Drug: dasotraline
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dasotraline 8mg capsule/day
Study: NCT00102687
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.
Study: NCT00865514
Drug: Dichloroacetate
Normalized name: Dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
Study: NCT04570397
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
Study: NCT02438982
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
Study: NCT02438982
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
Study: NCT02054949
Drug: N-Acetyl Cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
Study: NCT03519984
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03519984
Drug: Vincristine Liposomal
Normalized name: vincristine liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03902002
Drug: Omaveloxolone 50 mg capsules
Normalized name: omaveloxolone
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 50 mg of omaveloxolone
Study: NCT04272203
Drug: ABBV-184
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT03851588
Drug: Dolutegravir 50 mg
Normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
Study: NCT00932282
Drug: Peanut Oral Immunotherapy
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
Study: NCT00932282
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
Study: NCT00147160
Drug: Temozolomide, Cisplatinum
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00802282
Drug: psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose manipulation as described in the protocol and to which volunteers are blinded
Study: NCT00176631
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
Study: NCT02947620
Drug: Metformin/Atorvastatin 1500mg/40mg, QD
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02947620
Drug: Metformin 1500mg, QD
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02947620
Drug: Atorvastatin 40mg, QD
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02944474
Drug: Lucerastat
Normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration containing lucerastat
Study: NCT00303667
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
Study: NCT00303667
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
Study: NCT00303667
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
Study: NCT01021267
Drug: Saw palmetto berry extract
Normalized name: saw palmetto berry extract
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x daily 1 capsule containing 320mg lipophilic extract
Study: NCT00334256
Drug: Tenofovir (TDF)
Normalized name: emtricitabine/tenofovir (TDF) 200 mg-300 mg ORAL TABLET
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00334256
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02135965
Drug: 2mg of Albuterol
Normalized name: albuterol 2 MG
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg of Albuterol on metabolic rate
Study: NCT02135965
Drug: 4mg of Albuterol
Normalized name: albuterol 4 MG
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg of Albuterol on metabolic rate
Study: NCT03016338
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 or 300 mg daily PO, for 21 day cycle
Study: NCT01829919
Drug: Brisdelle (paroxetine mesylate)
Normalized name: Brisdelle
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
Study: NCT06231459
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
Study: NCT01690975
Drug: Benzonatate - 400 mg
Normalized name: Benzonatate
DrugBank: Benzonatate (DB00868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzonatate - 400 mg single dose
Study: NCT01690975
Drug: Benzonatate - 600 mg
Normalized name: Benzonatate
DrugBank: Benzonatate (DB00868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzonatate - 600 mg single dose
Study: NCT00834899
Drug: Eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
Study: NCT00933283
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
Study: NCT04492618
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
Study: NCT00933283
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
Study: NCT01094028
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
Study: NCT00003242
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003242
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003242
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02182167
Drug: Water
Normalized name: Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483587
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
Study: NCT01298778
Drug: Duramorph 150
Normalized name: Duramorph
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
Study: NCT01298778
Drug: Duramorph 300
Normalized name: Duramorph
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
Study: NCT00767520
Drug: Exemestane + Dasatinib
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
Study: NCT00767520
Drug: Exemestane + Placebo
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
Study: NCT01037582
Drug: NN9924 (s.c.)
Normalized name: factor IX / factor VII / factor X / protein C / protein S / prothrombin Injection [Kcentra]
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
Study: NCT01037582
Drug: NN9924 (i.v.)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
Study: NCT00722631
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
Study: NCT00722631
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
Study: NCT03910660
Drug: BXCL701 plus Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle.
Study: NCT03910660
Drug: BXCL701 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.
Study: NCT00632086
Drug: aspirin component of PA32540
Normalized name: TRAVOPROST COMPONENT OF DUOTRAV
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The 325 mg aspirin component of PA32540
Study: NCT00632086
Drug: Ecotrin
Normalized name: Ecotrin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325 mg Ecotrin
Study: NCT00888784
Drug: beta-blocker (propranolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study: NCT02062034
Drug: Ubiquinone
Normalized name: Ubiquinone
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg daily of oral ubiquinone for 24 weeks
Study: NCT02562417
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00058214
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02191007
Drug: Calcipotriol Betamethasone ointment and Calcipotriol ointment
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02191007
Drug: Calcipotriol Betamethasone ointment
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02443545
Drug: Deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02401477
Drug: Ilaprazole + Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
Study: NCT01397708
Drug: INXN-1001
Normalized name: DNA (RECOMBINANT LENTIVIRUS VECTOR INXN-2004-TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
DrugBank: Dabocemagene autoficel (DB17878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)
Study: NCT03808870
Drug: NBM-BMX softgel capsules
Normalized name: docusate sodium Oral Capsule [Correctol Softgel Extra Gentle]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Study: NCT00402220
Drug: TMS
Normalized name: TMTMS
DrugBank: Tetramethylthiuram monosulfide (DB14178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Transcranial Magnetic Stimulation
Study: NCT00788229
Drug: AT01
Normalized name: MaaT013
DrugBank: MaaT013 (DB18648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drop for 12 weeks
Study: NCT00788229
Drug: AT02
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eye drop for 12 weeks
Study: NCT00788229
Drug: AT03
Normalized name: KARAYA GUM WASHER,TORBOT #AT0312
DrugBank: Karaya gum (DB10535)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drop for 12 weeks
Study: NCT00788229
Drug: AT04
Normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eye drop for 12 weeks
Study: NCT00052026
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose carvedilol administered twice daily for 8 months
Study: NCT00052026
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose carvedilol administered twice daily for 8 months
Study: NCT02516423
Drug: ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT02516423
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT02516423
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT03794518
Drug: Pioglitazone Plus dapaglifliozin
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone Plus dapaglifliozin
Study: NCT02761213
Drug: Oral sulfate solution (OSS)
Normalized name: Oral Film
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution (OSS)
Study: NCT00531349
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia
Study: NCT00478569
Drug: Parathyroid Hormone (PTH) (1-84)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adherence to PTH(1-84) treatment in Usual Clinical Settings
Study: NCT03407521
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction of abortion using misoprostol